Anti-PD-(L)1 monotherapies have been proven to be effective treatments for many types of cancer, but response rates remain low, with only 18–45% of patients showing complete or partial tumor regression in clinical trials (Sun et al., 2018). Here, CD274 is linked to neoplasm.